Independent software research / Pharma and life sciences, small-emerging through large pharma
The yardstick for AI in pharma and life sciences - calibrated for your size tier, focus, and stack.
We test every B2B AI vendor on the same rubric, and we score for what pharma and life-sciences operators actually buy: medical, legal, and regulatory cycle time; field-rep next-best-action acceptance; trial-enrollment velocity; manufacturing right-first-time; discovery cycle from lead identification to candidate selection. The audit routes by size tier (small or emerging biopharma under $500M, mid-size $500M to $5B, large pharma over $5B) and by focus area (Research and Development, clinical development, manufacturing, commercial, medical affairs, patient services). Medical-device companies are not in scope; if you sell devices, this audit does not fit your business. COOs, Chief Commercial Officers, Chief Scientific Officers, and CIOs choose on evidence, not vendor demos.
Take the free 4-minute pharma and life sciences auditHow we test, score, and publish
Yardstick Research is an independent software research and consulting agency for B2B AI tools. We test the tools ourselves, score them on outcomes that matter, and publish the results. Methodology in plain sight, so any board or compliance committee can check our work. For pharma and life-sciences operators, we weight Data Readiness and Budget & Procurement heavily. In this industry your Veeva, IQVIA, and Komodo footprint determines what AI you can actually deploy, and the procurement timeline for a regulated tool is measured in quarters, not weeks. Here's how that actually happens:
-
01
We evaluate every pharma and life-sciences vendor on this list using public information and free-tier hands-on.
Our researchers evaluate each vendor on the list using a defensible mix of inputs: vendor documentation and pricing pages, free-tier or trial-seat hands-on where the vendor offers one, video walkthroughs, third-party reviews (G2, Capterra, Gartner Peer Insights, KLAS), published customer case studies, practitioner discussion (LinkedIn, Endpoints News, BioPharma Dive, STAT), and recent funding and news coverage. Where we can sign up and exercise the product directly, we do, and grade the output against a sample workflow: in the pharma case, a medical, legal, and regulatory review draft; a next-best-action recommendation against a sample territory; or a real-world-evidence query against published claims data. We do not pay for paid tiers and we do not run a held-out clinical-validation study through every tool. Both are cost-prohibitive at the scale this guide covers. Medical-device companies are out of scope: we do not score device-specific 510(k) workflows, in-vitro diagnostics, or surgical-robotics platforms.
Every claim in a tear-sheet is labelled MEASURED (free-tier hands-on observation, or output graded against a sample workflow), ESTIMATED (cost-per-seat efficiency derived from the vendor's pricing page and feature limits), or CITED (vendor-published or third-party benchmark, with the source linked).
-
02
We score on outcomes buyers care about, with weights we publish.
Vendor decks sell features. Pharma operators actually buy outcomes: medical, legal, and regulatory cycles that drop below two weeks; next-best-action acceptance above 50 percent; clinical-trial enrollment that stays inside 90 percent of the original timeline; manufacturing right-first-time above 95 percent; and a stack that survives FDA 21 CFR Part 11, Good Clinical Practice and Good Manufacturing Practice review, HIPAA, EMA GDPR, pharmacovigilance reporting, and any Office of Inspector General corporate-integrity agreement you're under. We score five dimensions: Strategy & Use Cases, Data Readiness, Tool Stack, Team & Workflow, and Budget & Procurement. Industry benchmarks for mature pharma and life-sciences operators sit at 65 / 70 / 50 / 60 / 70 percent of each dimension's maximum. The audit routes by size tier (small or emerging, mid-size, large pharma) and focus area (Research and Development, clinical, manufacturing, commercial, medical affairs, patient services), and captures your operating baselines plus your Inflation Reduction Act exposure and Pharmacy Benefit Manager contracting posture for mid-size and large-pharma operators. The dimensions and benchmarks are public so your board can defend the pick, and so vendors can't quietly negotiate them.
-
03
We publish. Vendors check facts. Affiliate links are disclosed.
Every vendor receives their scored tear-sheet seven days before publication and can flag factual errors (wrong pricing tier, misquoted feature, integration listed as native that's actually via a third party). Rankings can't be appealed; only factual corrections are accepted. Where the guide links to a vendor's product, that link may earn us a commission. Disclosed on every page where the link appears. Vendors do not pay for inclusion, placement, or ranking.
Take the audit
See your score
Get your results
Free. Calibrated for pharma and life sciences operators
AI Readiness Audit. Pharma & Life Sciences edition
Select Your Industry
This audit is for pharma and life sciences operators - small-emerging biotech, mid-size, and large pharma - evaluating AI for R&D, clinical, manufacturing, commercial, medical affairs, or patient services. Medical-device companies are not in scope. If you are a hospital, clinic, or health system evaluating AI for your own clinical operations, take the Clinical Workflow audit instead.
AI clinical-workflow tools, scored
Twelve platforms scored on a published seven-dimension rubric weighted toward clinical accuracy, EHR integration depth, and PHI posture. Full rubric on the methodology page. Each card expands to show the dimension breakdown, top strength, top gap, and best-fit notes.
01 Ambience Healthcare Desk research Ambient scribe + auto-coding (Epic / Cerner / Athena) 75.63 /100
Top strength Best multi-modal stack on this list. Deployed at Cleveland Clinic, Houston Methodist, John Muir, Memorial Hermann, St. Luke's, Ardent Health at multi-thousand-clinician scale. Best Epic embed on this list via Toolbox + Hyperdrive + Haiku.
Top gap No published Ambience-specific hallucination rate or peer-reviewed validation study. No Meditech / eClinicalWorks integration (hard penalty for those buyers). Compliance posture caps at SOC 2 + HIPAA BAA; HITRUST CSF + training-on-PHI default both undocumented.
Best for Epic / Cerner / Athena enterprise health systems. Scale and Optimization stages.
02 Microsoft DAX Copilot Desk research Ambient scribe + Epic embed (rebranded Dragon Copilot Mar 2025) 72.5 /100
Top strength Deepest Epic embed on this list. 600+ health systems; 100,000+ cumulative clinicians named (Stanford, Intermountain, Mass General Brigham, Mount Sinai, Vanderbilt, Providence). Five published peer-reviewed studies. UKCA Class I device mark.
Top gap Pricing opacity: $369 (reseller) to $1,512/user/month (analyst-published) range. NEJM AI longitudinal contradicts Stanford QI study. UCLA RCT: DAX -1.7% time-in-note (not significant) vs Nabla -9.5% (p=0.02). Base LLM not named.
Best for Epic-anchored academic medical centers and large IDNs. Pilot and Scale stages.
03 Abridge Desk research Ambient scribe (KLAS #1, Kaiser 24K deployment) 68.75 /100
Top strength KLAS-rated #1 ambient AI scribe. Kaiser 24K + Duke 5K + 150+ health-system footprint. $117M Q1 2025 contracted ARR. 50M annualized medical conversations. Linked Evidence UI is the list's strongest provenance feature.
Top gap Underlying LLM stack undisclosed. HITRUST absent; model-training opt-out default undocumented. Active California class-action Saucedo v Sharp HealthCare Nov 2025 alleges vendor-side deletion-on-demand gap (class >100K patient encounters).
Best for Epic-deep enterprise health systems. Premium pricing band; Pilot and Scale stages.
04 Suki AI Desk research Voice-first ambient scribe + EHR assistant 57.5 /100
Top strength Strongest voice-first option on this list. Broadest EHR coverage (4 EHRs bidirectional). Phyx 2025 study (116 PCPs, p<0.001 burnout reduction). MedStar thousands-of-clinicians deployment. KLAS 93.2 + 95% buy-again.
Top gap Highest priced on this list ($299-$399/provider/month). HITRUST CSF tier not surfaced. No published clinical benchmarks (MedQA/MedHELM/MedBench). LLM Manager routes across OpenAI/Anthropic/Gemini - no committed foundation model.
Best for Voice-first ambient scribe workflows. Mid-market and enterprise. Pilot stage.
05 Regard Desk research Pre-encounter chart-reading clinical copilot 55 /100
Top strength Differentiated workflow: drafts notes BEFORE the encounter by reading the full chart (complementary to ambient scribes, not competitive). Banner Health 33-hospital enterprise rollout + Cedars-Sinai Sept 2025 dual-hospital start. Microsoft Dragon Copilot integration Oct 2025.
Top gap No peer-reviewed validation. No published hallucination rate. /security, /trust, /trust-center all 404 as of 2026-05-17. Founder roster discrepancy (Thomas Moulia on Crunchbase, absent from /about). Sentara / Penn Highlands attribution conflict on $7M revenue figure.
Best for Inpatient hospitalist workflows complementary to ambient scribes. Pilot and Scale stages.
06 Iodine (Waystar) Desk research CDI (acquired by Waystar Oct 1, 2025; $1.25B EV) 53.75 /100
Top strength Largest clinical dataset in CDI (27%+ of US inpatient discharges; 900+ to 1,000+ hospitals). HITRUST certified. SOC 2 confirmed. Strong HL7 v2 / data-feed integration proven by customer base.
Top gap Post-acquisition customer-experience wobble (Best in KLAS lost to Microsoft Nuance CDI 2024+2025; KLAS VP-reviewer flagged 'almost a complete turnover'). No Epic App Orchard / Cerner CODE listing. Training-data opt-out posture undocumented. OpenAI sub-processor contractual structure undisclosed.
Best for Hospitals with existing HL7 v2 integration appetite + Waystar relationships. Change-of-control termination right is contract-critical.
Acquired by Waystar Oct 1, 2025 for $1.25B EV. iodinesoftware.com 301-redirects to waystar.com. KLAS score declined 90.0 -> 86.1 -> 85.1 -> 83.5 across 2023-2026; Microsoft Nuance CDI took Best in KLAS 2024 + 2025. Headcount dropped 264 -> 131 Jul-Jan post-acquisition.
07 Cohere Health Desk research Payor-side prior-authorization + utilization-management AI 53.1 /100
Top strength Most operationally mature payor-side PA vendor. 12M+ annual PA volume; 16M+ covered lives. HITRUST r2 + URAC + NCQA certified. Strong commercial-payor case studies (Humana, Geisinger).
Top gap Foundation LLM not publicly named. SOC 2 Type II not disclosed. No peer-reviewed validation on PA-determination accuracy. Texas WISeR Q1 2026 field data (62% first-try approval) contradicts commercial-payor case studies. WISeR share-of-savings (10-20% of averted expenditures) compensation model warrants buyer scrutiny.
Best for Health systems with Cohere-contracted payor relationships (Humana, etc.). Conditional Pilot fit only.
08 Notable Desk research Healthcare workflow automation (intake + RCM + care operations) 49.4 /100
Top strength Most legitimate healthcare workflow automation vendor post-Olive AI. MUSC 1.5M tasks/day, CommonSpirit ~1.05M touchpoints in 2024 are production-scale signals. Named: CommonSpirit, MUSC, Catholic Health, Montage, Florida + NY health systems. Meditech support is a category strength vs ambient-scribe peers.
Top gap Workflow automation, not clinical-decision-support / ambient-scribe (cohort-fit caveat declared). HARD integration penalty for eClinicalWorks / NextGen / Allscripts / Veradigm. No LLM disclosure. No published FHIR R4 / SMART on FHIR conformance. No peer-reviewed validation. No publicly disclosed funding round since November 2021 ($100M Series B at $600M) - peers raised at frontier-AI multiples in the same window.
Best for Health systems on Epic / Cerner / Athena / Meditech that need patient access / RCM / care-gap outreach automation. Not clinical decisions.
09 Tennr Desk research AI intake + faxes + referral processing 48.75 /100
Top strength Strongest DME / specialty / infusion / home-medical intake automation on this list. 10M+ documents/month, 150+ healthcare orgs, $605M valuation. Concrete falsifiable named-customer outcomes. RaeLM model architecture published.
Top gap Trust + customers pages return 404 as of 2026-05-17 (procurement-friction signal). HITRUST status / level / target date not claimed. Whether customer PHI is excluded from RaeLM training by default in standard DPA undocumented. No Epic App Orchard / Cerner CODE / SMART on FHIR conformance.
Best for DME / specialty / infusion / home-medical groups. Workflow automation, not clinical decision. Pilot stage.
10 Glass Health Desk research Self-serve clinical decision support + scribe 46.9 /100
Top strength Best self-serve CDS + scribe experience on this list for solo physicians and small ambulatory groups. Glass 5.5 Deep Reasoning / Standard tiers. Lowest entry price.
Top gap Underlying foundation model not disclosed (procurement-blocking for hospital InfoSec). SOC 2 Type II + HITRUST CSF status not publicly documented; /security returns 404. EHR write-back scope per EHR (notes only vs orders + problem-list) not enumerated. Named institutions (Harvard, Stanford, Johns Hopkins) are individual-clinician users, not enterprise contracted deployments.
Best for Solo physicians and small ambulatory groups. Foundation- and Pilot-stage only. Not yet enterprise-ready.
11 Adonis Intelligence Desk research RCM-AI orchestration (cohort-fit caveat) 43.4 /100
Top strength $95M+ raised across Seed to Series C; >4x revenue growth in 2025. Net retention above 130%. Named: Mount Sinai, Baptist Health South Florida, AdventHealth, ApolloMD, Redefine Healthcare. Stedi clearinghouse stack (3,400+ US payors via 837P / 835).
Top gap RCM-not-clinical-workflow - the rubric undervalues the product. LLM / agent architecture entirely undisclosed. Model-training opt-out default undocumented. HITRUST CSF tier (r2/e1/i1) + SOC 2 Type II audit date not published. No FHIR R4 / SMART on FHIR conformance.
Best for Health systems prioritizing RCM automation over clinical-workflow AI. Re-classification candidate for a future RCM-AI vendor list.
12 Hippocratic AI Desk research Clinician-supervised AI voice agents (3 controversies) 41.9 /100
Top strength 115M+ patient-facing voice interactions across non-diagnostic outreach. HITRUST e1 certified. Series C $126M at $3.5B valuation Nov 2025 led by Avenir Growth. 50+ enterprise partners.
Top gap Three live controversies (founder Chapter 7 tail, Polevikov 'Theranos 2.0' allegations, labor union opposition). No EHR write-back. No FHIR / SMART on FHIR. PHI-training-opt-out default undocumented. Foundation model behind Polaris constellation not named in arXiv paper.
Best for Non-diagnostic outbound patient-voice outreach campaigns only. Conditional Pilot fit; not Scale or Optimization.
Three live controversies flagged: (1) Founder Munjal Shah's prior Health IQ filed Chapter 7 Aug 2023 with $256.7M liabilities + 17 pending breach-of-contract suits. (2) Polevikov 'Theranos 2.0' allegations (contested) - ~$17-20M ARR vs $404M burn, >80% call concentration in one client. (3) NNU + CNA + WSHA labor opposition + Sept 23 2025 protest at 22 Kaiser facilities.